癌症疫苗市场规模、份额、趋势分析报告:按适应症类型、疫苗类型、技术类型、地区和细分市场趋势:2023-2030
市场调查报告书
商品编码
1321366

癌症疫苗市场规模、份额、趋势分析报告:按适应症类型、疫苗类型、技术类型、地区和细分市场趋势:2023-2030

Cancer Vaccine Market Size, Share & Trends Analysis Report By Indication Type (Bladder, Cervical), By Vaccine Type (Preventive, Therapeutic), By Technology Type (Recombinant, Whole-cell), By Region, And Segment Forecasts, 2023 - 2030

出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

癌症疫苗市场成长与趋势

Grand View Research, Inc.最新报告显示,预计2023年至2030年全球癌症疫苗市场规模将以11.04%的年复合成长率成长,2030年将达到168.4亿美元。

人口中癌症盛行率的增加推动了市场的成长。根据世界卫生组织统计,癌症是全球头号死亡原因,2020年将有1000万人死亡,其中前列腺癌、肺癌、乳腺癌、结肠癌、皮肤癌和胃癌最为常见。人死了。病例数的增加很大程度上是由于多种要素造成的,包括老年人口的增加以及经济和社会发展导致特定癌症病因盛行率的变化。这在新兴经济体尤其明显,在这些经济体中,与贫穷相关的癌症发生了普遍变化。这与已开发经济体形成鲜明对比,在已开发经济体,越来越多的病例与生活方式障碍有关。

世界卫生组织表示,肥胖、某些感染疾病和辐射暴露是导致病例增加的主要要素。此外,预防领域的技术进步显着增加了全球对疫苗的需求。 FDA 支持生物标记和质谱流式细胞仪的开发,推出用于药物研发和诊断的多种流式细胞术试剂,技术先进的微型化设备,有利于便携性和精确性,基于细胞和珠子的流式细胞仪技术的开拓是推动市场成长的主要要素。各组织为提高人们对癌症的认识而开展的各种计划是全球创新疫苗需求不断增长的一个主要要素。国家子宫颈癌联盟、疾病预防控制中心、世界卫生组织、美国预防服务工作小组等为增加子宫颈癌筛检而进行的合作和伙伴关係是预计在预测期内增加市场成长的关键因素。这是要素。

此外,参与各种疫苗开发和配製的主要公司正在专注于联合研究和联盟,以开发新疫苗并保持行业竞争力。此外,多家公司正在致力于开发新疫苗,以满足预防这种疾病不断增长的需求。例如,2023年2月,BioNTech宣布计画从2023年9月开始对其疫苗进行临床试验,预计疫苗将于2030年上市。 2023 年 3 月,克利夫兰诊所的调查团队宣布了将最致命的预防三阴性乳癌疫苗推向市场的下一步措施。

癌症疫苗市场报告亮点

  • 2022年,由于盛行率上升导致疾病预防的需要,预防性疫苗类型占据最大的销售份额。
  • 由于盛行率上升,预计子宫颈癌适应症类型在预测期内将出现最快的增长速度。
  • 从技术类型来看,由于重组技术开发的疫苗具有高可用性,重组疫苗领域将在 2022 年占据全球产业的主导地位。
  • 主要企业不断专注于产品发布和地理扩张,以保持其市场地位和份额。
  • 由于其发达的医疗基础设施、高癌症盛行率、主要企业的存在以及适当的疫苗接种服务的可用性,北美将在 2022 年占据最大的销售份额。

目录

第1章癌症疫苗市场:调查方法与范围

第2章癌症疫苗市场:执行摘要

  • 市场简介
  • 疫苗类型和适应症类型概况
  • 技术类型简介
  • 竞争形势概览

第3章癌症疫苗市场:产业展望

  • 市场体系预测
    • 母市场谱系预测
    • 相关/附随市场预测
  • 普及和成长预测图
  • 市场动态
    • 市场促进因素
    • 市场抑制因素分析
  • 要素因素(政治/法律、经济/技术)进行 SWOT 分析
  • 产业分析-波特
  • 赎回和法规场景
  • 主要交易和战略联盟
    • 新产品发布
    • 获得
    • 扩张
    • 合伙
    • 行销和推广

第4章癌症疫苗市场:竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 供应商形势
  • 上市公司
  • 私人公司
  • 区域网路图

第5章癌症疫苗市场:疫苗类型商业分析

  • 定义和范围
  • 2022 年和 2030 年疫苗类型市占率分析
  • 2018-2030 年全球癌症疫苗市场(以疫苗类型)
  • 癌症疫苗市场:疫苗类型变异分析
  • 癌症预防疫苗
  • 治疗性癌症疫苗
  • 其他的

第6章癌症疫苗市场:按适应症类型进行的业务分析

  • 定义和范围
  • 2022 年和 2030 年按适应症类型分類的市场份额分析
  • 全球癌症疫苗市场,适应症类型,2018-2030
  • 癌症疫苗市场:适应症类型波动分析
  • 摄护腺癌
  • 膀胱癌
  • 黑色素瘤
  • 子宫颈癌
  • 其他的

第7章癌症疫苗市场:技术类型的商业分析

  • 定义和范围
  • 2022 年及 2030 年技术类型市占率分析
  • 2018-2030 年全球癌症疫苗市场(依技术类型)
  • 癌症疫苗市场:技术类型变化分析
  • 重组癌症疫苗
  • 全细胞癌症疫苗
  • 病毒载体和 DNA 癌症疫苗
  • 其他的

第8章癌症疫苗市场:区域业务分析

  • 定义和范围
  • 2022 年及 2030 年区域市占率分析
  • 区域市场仪表板
  • 区域市场简介
  • 要素因素(政治/法律、经济/技术)进行 SWOT 分析
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东/非洲
  • 2022年至2030年市场规模、预测、趋势分析
  • 北美洲
    • 2018年至2030年北美疫苗市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 欧洲癌症疫苗市场,2018-2030
    • 英国
    • 德国
    • 西班牙
    • 法国
    • 义大利
    • 挪威
    • 丹麦
    • 瑞典
  • 亚太地区
    • 亚太地区癌症疫苗市场,2018-2030
    • 日本
    • 中国
    • 印度
    • 韩国
    • 泰国
    • 澳洲
  • 拉丁美洲
    • 拉丁美洲癌症疫苗市场,2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • MEA 癌症疫苗市场,2018-2030
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第9章癌症疫苗市场:公司简介

  • 公司分类
  • 策略规划
    • 新产品发布
    • 合伙
    • 获得
    • 合作
    • 资金筹措
  • 2022年主要企业市占率分析
  • 公司简介
    • Merck & Co., Inc.
    • GSK plc
    • Dendreon Pharmaceuticals LLC.
    • Dynavax Technologies.
    • Ferring BV
    • Amgen, Inc.
    • Moderna, Inc.
    • Sanofi
    • AstraZeneca
    • Bristol-Myers Squibb Company
Product Code: GVR-4-68040-096-2

Cancer Vaccine Market Growth & Trends

The global cancer vaccine market size is expected to reach USD 16.84 billion by 2030, expanding at a CAGR of 11.04% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market growth is attributed to the increasing prevalence of cancer among the population. According to the WHO, it is a leading cause of death globally, which accounted for 10 million deaths in 2020, with prostate, lung, breast, colon, skin, and stomach cancers being the most common types causing one in every six deaths worldwide. A rise in the number of cases can be majorly attributed to various factors, such as the rising geriatric population and changing prevalence of certain causes of cancer associated with economic & social development. This is particularly seen in emerging economies, wherein a general shift is observed in terms of cancers associated with poverty, which is a contrast to developed economies, wherein cases have increasingly been associated with lifestyle disorders.

According to the WHO, obesity, certain types of infections, and exposure to radiation are major factors associated with an increase in the number of cases. Moreover, the demand for vaccines is significantly increasing worldwide owing to technological advancements in the field of prevention. FDA support for developing biomarkers & mass cytometry; launch of various flow cytometry reagents for drug discovery & diagnosis; technologically advanced miniaturized devices, facilitating portability & precision; development of cell- & bead-based flow cytometry techniques are major factors boosting the market growth. Various programs to increase awareness about cancer by organizations are key factors responsible for the increased demand for innovative vaccines worldwide. Collaborations and partnerships undertaken by the National Cervical Cancer Coalition, CDC, WHO, the U.S. Preventive Services Task Force, and others for increasing screening of cervical cancer are major factors expected to augment the market growth during the forecast period.

Furthermore, key players involved in developing and formulating various vaccines are focusing on collaborations and partnerships to develop novel vaccines and to maintain their competitive position in the industry. Moreover, several players are involved in the development of novel vaccines to meet the rising demand for prevention of the condition. For instance, in February 2023, BioNTech announced plans to proceed with clinical trials for its vaccine from September 2023, which is expected to be launched in the market before 2030. In March 2023, Researchers at Cleveland Clinic announced the next step toward the launch of a vaccine for the prevention of triple-negative breast cancer, which is one of the most lethal forms of the condition.

Cancer Vaccine Market Report Highlights

  • The preventive vaccine type segment held the largest revenue share in 2022 owing to the need for preventing the condition due to the rising prevalence
  • The cervical cancer indication type segment is expected to register the fastest growth rate over the forecast period due to the rising disease prevalence
  • On the basis of technology type, the recombinant vaccine segment dominated the global industry in 2022 due to the high availability of vaccines developed from recombinant technology
  • Key players operating are constantly focusing on product launches and geographical expansions to maintain their market position and share
  • North America held the largest revenue share in 2022 on account of the better healthcare infrastructure, the high prevalence of cancer, the presence of key players, and the availability of proper vaccination service

Table of Contents

Chapter 1 Cancer Vaccine Market: Methodology And Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment Definitions
      • 1.1.1.1 Vaccine Type Segment
      • 1.1.1.2 Technology type segment
      • 1.1.1.3 Indication type segment
  • 1.2 Regional Scope
  • 1.3 Estimates and Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 Gvr's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List of Secondary Sources
  • 1.11 List of Abbreviations

Chapter 2 Cancer Vaccine Market: Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Vaccine Type and Indication Type Snapshot
  • 2.3 Technology Type Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Cancer Vaccine Market: Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Lineage Outlook
    • 3.1.2 Related/Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Market Dynamics
    • 3.3.1 Market Drivers
      • 3.3.1.1 Increasing Prevalence of cancer
      • 3.3.1.2 Growing investments and governmental funding in the development of cancer vaccines
      • 3.3.1.3 Increasing demand for cancer vaccines
      • 3.3.1.4 Launch of new cancer vaccines
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Complex And Time-Consuming Regulatory Approval Process
      • 3.3.2.2 High Price Associated With Vaccines
  • 3.4 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
  • 3.5 Industry Analysis - Porter's
  • 3.6 Reimbursement & Regulatory Scenario
  • 3.7 Major Deals & Strategic Alliances
    • 3.7.1 New Product Launch
    • 3.7.2 Acquisition
    • 3.7.3 Expansion
    • 3.7.4 Partnerships
    • 3.7.5 Marketing & Promotions

Chapter 4 Cancer Vaccine Market: Competitive Landscape

  • 4.1 Recent developments & impact analysis, by key market participants
    • 4.1.1 Ansoff Matrix
  • 4.2 Company Categorization
    • 4.2.1 Innovators
      • 4.2.1.1 Market Differentiators
  • 4.3 Vendor Landscape
    • 4.3.1 List Of Key Distributors And Channel Partners
    • 4.3.2 Key Customers
    • 4.3.3 Key Company Market Share Analysis, 2022
  • 4.4 Public Companies
    • 4.4.1 Competitive Dashboard Analysis
  • 4.5 Private Companies
    • 4.5.1 List Of Key Emerging Companies
  • 4.6 Regional Network Map

Chapter 5 Cancer Vaccine Market: Vaccine Type Business Analysis

  • 5.1 Definition And Scope
  • 5.2 Vaccine Type Market Share Analysis, 2022 & 2030
  • 5.3 Global Cancer Vaccine Market, By Vaccine Type, 2018 To 2030
  • 5.4 Cancer Vaccine Market: Vaccine Type Movement Analysis
  • 5.5 Preventive Cancer Vaccines
    • 5.5.1 Preventive Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6 Therapeutic Cancer Vaccines
    • 5.6.1 Therapeutic Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.7 Others
    • 5.7.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Cancer Vaccine Market: Indication Type Business Analysis

  • 6.1 Definition And Scope
  • 6.2 Indication Type Market Share Analysis, 2022 & 2030
  • 6.3 Global Cancer Vaccine Market, By Indication Type, 2018 To 2030
  • 6.4 Cancer Vaccine Market: Indication Type Movement Analysis
  • 6.5 Prostate Cancer
    • 6.5.1 Prostate Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.6 Bladder Cancer
    • 6.6.1 Bladder Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.7 Melanoma
    • 6.7.1 Melanoma Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.8 Cervical Cancer
    • 6.8.1 Cervical Cancer Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.9 Others
    • 6.9.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7 Cancer Vaccine Market: Technology Type Business Analysis

  • 7.1 Definition And Scope
  • 7.2 Technology Type Market Share Analysis, 2022 & 2030
  • 7.3 Global Cancer Vaccine Market, By Technology Type, 2018 To 2030
  • 7.4 Cancer Vaccine Market: Technology Type Movement Analysis
  • 7.5 Recombinant Cancer Vaccines
    • 7.5.1 Recombinant Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.6 Whole-Cell Cancer Vaccines
    • 7.6.1 Whole-Cell Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.7 Viral Vector And Dna Cancer Vaccines
    • 7.7.1 Viral Vector And Dna Cancer Vaccines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.8 Others
    • 7.8.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 Cancer Vaccine Market: Regional Business Analysis

  • 8.1 Definition & Scope
  • 8.2 Regional Market Share Analysis, 2022 & 2030
  • 8.3 Regional Market Dashboard
  • 8.4 Regional Market Snapshot
  • 8.5 Swot Analysis, By Factor (Political & Legal, Economic And Technological)
    • 8.5.1 North America
    • 8.5.2 Europe
    • 8.5.3 Asia Pacific
    • 8.5.4 Latin America
    • 8.5.5 Mea
  • 8.6 Market Size, & Forecasts, Trend Analysis, 2022 To 2030
  • 8.7 North America
    • 8.7.1 North America Cancer Vaccine Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 8.7.2 U.S.
      • 8.7.2.1 U.S. Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.7.2.2 Key Country Dynamics
      • 8.7.2.3 Regulatory Framework
      • 8.7.2.4 Competitive Scenario
    • 8.7.3 Canada
      • 8.7.3.1 Canada Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.7.3.2 Key Country Dynamics
      • 8.7.3.3 Regulatory Framework
      • 8.7.3.4 Competitive Scenario
  • 8.8 Europe
    • 8.8.1 Europe Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 8.8.2 UK
      • 8.8.2.1 UK Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.2.2 Key Country Dynamics
      • 8.8.2.3 Regulatory Framework
      • 8.8.2.4 Competitive Scenario
    • 8.8.3 Germany
      • 8.8.3.1 Germany Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.3.2 Key Country Dynamics
      • 8.8.3.3 Regulatory Framework
      • 8.8.3.4 Competitive Scenario
    • 8.8.4 Spain
      • 8.8.4.1 Spain Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.4.2 Key Country Dynamics
      • 8.8.4.3 Regulatory Framework
      • 8.8.4.4 Competitive Scenario
    • 8.8.5 France
      • 8.8.5.1 France Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.5.2 Key Country Dynamics
      • 8.8.5.3 Regulatory Framework
      • 8.8.5.4 Competitive Scenario
    • 8.8.6 Italy
      • 8.8.6.1 Italy Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.6.2 Key Country Dynamics
      • 8.8.6.3 Regulatory Framework
      • 8.8.6.4 Competitive Scenario
    • 8.8.7 Norway
      • 8.8.7.1 Norway Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.7.3 Regulatory Framework
      • 8.8.7.4 Competitive Scenario
    • 8.8.8 Denmark
      • 8.8.8.1 Denmark Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.8.2 Key Country Dynamics
      • 8.8.8.3 Regulatory Framework
      • 8.8.8.4 Competitive Scenario
    • 8.8.9 Sweden
      • 8.8.9.1 Sweden Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.8.9.2 Key Country Dynamics
      • 8.8.9.3 Regulatory Framework
      • 8.8.9.4 Competitive Scenario
  • 8.9 Asia Pacific
    • 8.9.1 Asia-Pacific Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 8.9.2 Japan
      • 8.9.2.1 Japan Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.2.2 Key Country Dynamics
      • 8.9.2.3 Regulatory Framework
      • 8.9.2.4 Competitive Scenario
    • 8.9.3 China
      • 8.9.3.1 China Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.3.2 Key Country Dynamics
      • 8.9.3.3 Regulatory Framework
      • 8.9.3.4 Competitive Scenario
    • 8.9.4 India
      • 8.9.4.1 India Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.4.2 Key Country Dynamics
      • 8.9.4.3 Regulatory Framework
      • 8.9.4.4 Competitive Scenario
    • 8.9.5 South Korea
      • 8.9.5.1 South Korea Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.5.2 Key Country Dynamics
      • 8.9.5.3 Regulatory Framework
      • 8.9.5.4 Competitive Scenario
    • 8.9.6 Thailand
      • 8.9.6.1 Thailand Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.6.2 Key Country Dynamics
      • 8.9.6.3 Regulatory Framework
      • 8.9.6.4 Competitive Scenario
    • 8.9.7 Australia
      • 8.9.7.1 Australia Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.9.7.2 Key Country Dynamics
      • 8.9.7.3 Regulatory Framework
      • 8.9.7.4 Competitive Scenario
  • 8.10 Latin America
    • 8.10.1 Latin America Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 8.10.2 Brazil
      • 8.10.2.1 Brazil Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.10.2.2 Key Country Dynamics
      • 8.10.2.3 Regulatory Framework
      • 8.10.2.4 Competitive Scenario
    • 8.10.3 Mexico
      • 8.10.3.1 Mexico Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.10.3.2 Key Country Dynamics
      • 8.10.3.3 Regulatory Framework
      • 8.10.3.4 Competitive Scenario
    • 8.10.4 Argentina
      • 8.10.4.1 Argentina Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.10.4.2 Key Country Dynamics
      • 8.10.4.3 Regulatory Framework
      • 8.10.4.4 Competitive Scenario
  • 8.11 MEA
    • 8.11.1 MEA Cancer Vaccine Market, 2018 - 2030 (USD Million)
    • 8.11.2 South Africa
      • 8.11.2.1 South Africa Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.11.2.2 Key Country Dynamics
      • 8.11.2.3 Regulatory Framework
      • 8.11.2.4 Competitive Scenario
    • 8.11.3 Saudi Arabia
      • 8.11.3.1 Saudi Arabia Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.11.3.2 Key Country Dynamics
      • 8.11.3.3 Regulatory Framework
      • 8.11.3.4 Competitive Scenario
    • 8.11.4 UAE
      • 8.11.4.1 UAE Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.11.4.2 Key Country Dynamics
      • 8.11.4.3 Regulatory Framework
      • 8.11.4.4 Competitive Scenario
    • 8.11.5 Kuwait
      • 8.11.5.1 Kuwait Cancer Vaccine Market, 2018 - 2030 (USD Million)
      • 8.11.5.2 Key Country Dynamics
      • 8.11.5.3 Regulatory Framework
      • 8.11.5.4 Competitive Scenario

Chapter 9 Cancer Vaccine Market: Company Profiling

  • 9.1 Company Categorization
  • 9.2 Strategy Mapping
    • 9.2.1 New Product Launch
    • 9.2.2 Partnerships
    • 9.2.3 Acquisition
    • 9.2.4 Collaboration
    • 9.2.5 Funding
  • 9.3 Key Company Market Share Analysis, 2022
  • 9.4 Company Profiles
    • 9.4.1 Merck & Co., Inc.
      • 9.4.1.1 Company Overview
      • 9.4.1.2 Financial Performance
      • 9.4.1.3 Product Benchmarking
      • 9.4.1.4 Strategic Initiatives
    • 9.4.2 GSK plc
      • 9.4.2.1 Company Overview
      • 9.4.2.2 Financial Performance
      • 9.4.2.3 Product Benchmarking
      • 9.4.2.4 Strategic Initiatives
    • 9.4.3 Dendreon Pharmaceuticals LLC.
      • 9.4.3.1 Company Overview
      • 9.4.3.2 Product Benchmarking
      • 9.4.3.3 Strategic Initiatives
    • 9.4.4 Dynavax Technologies.
      • 9.4.4.1 Company Overview
      • 9.4.4.2 Financial Performance
      • 9.4.4.3 Product Benchmarking
      • 9.4.4.4 Strategic Initiatives
    • 9.4.5 Ferring B.V.
      • 9.4.5.1 Company Overview
      • 9.4.5.2 Financial Performance
      • 9.4.5.3 Product Benchmarking
      • 9.4.5.4 Strategic Initiatives
    • 9.4.6 Amgen, Inc.
      • 9.4.6.1 Company Overview
      • 9.4.6.2 Financial Performance
      • 9.4.6.3 Product Benchmarking
      • 9.4.6.4 Strategic Initiatives
    • 9.4.7 Moderna, Inc.
      • 9.4.7.1 Company Overview
      • 9.4.7.2 Financial Performance
      • 9.4.7.3 Product Benchmarking
      • 9.4.7.4 Strategic Initiatives
    • 9.4.8 Sanofi
      • 9.4.8.1 Company Overview
      • 9.4.8.2 Financial Performance
      • 9.4.8.3 Product Benchmarking
      • 9.4.9.4 Strategic Initiatives
    • 9.4.9 AstraZeneca
      • 9.4.9.1 Company Overview
      • 9.4.9.2 Financial Performance
      • 9.4.9.3 Product Benchmarking
      • 9.4.9.4 Strategic Initiatives
    • 9.4.10 Bristol-Myers Squibb Company
      • 9.4.9.1 Company Overview
      • 9.4.9.2 Financial Performance
      • 9.4.9.3 Product Benchmarking
      • 9.4.9.4 Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Cancer Vaccine Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 5 Global Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 6 Global Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 7 North America Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 9 North America Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 10 North America Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 13 U.S. Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 16 Canada Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 18 Europe Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 19 Europe Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 20 Europe Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 21 UK Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 22 UK Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 23 UK Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 24 Germany Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 26 Germany Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 27 France Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 28 France Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 29 France Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 31 Italy Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 32 Italy Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 34 Spain Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 35 Spain Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 37 Denmark Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 38 Denmark Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 40 Sweden Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 41 Sweden Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 43 Norway Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 44 Norway Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 49 Japan Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 50 Japan Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 51 Japan Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 52 China Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 53 China Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 54 China Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 55 India Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 56 India Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 57 India Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 59 South Korea Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 60 South Korea Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 62 Australia Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 63 Australia Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 65 Thailand Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 66 Thailand Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 67 Latin America Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 68 Latin America Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 69 Latin America Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 70 Latin America Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 72 Brazil Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 73 Brazil Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 75 Mexico Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 76 Mexico Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 78 Argentina Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 79 Argentina Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Cancer Vaccine Market, By Country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 87 South Africa Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 88 South Africa Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 89 South Africa Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 91 UAE Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 92 UAE Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Cancer Vaccine Market, By Vaccine Type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Cancer Vaccine Market, By Indication Type, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Cancer Vaccine Market, By Technology Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Cancer Vaccine Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Cancer vaccine market: Vaccine Type outlook and key takeaways
  • Fig. 15 Cancer vaccine market: Vaccine Type movement analysis & market share 2022 & 2030
  • Fig. 16 Preventive cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 17 Therapeutic cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 18 Others market, 2018 - 2030 (USD Million)
  • Fig. 19 Cancer vaccine market: Indication type outlook and key takeaways
  • Fig. 20 Cancer vaccine market: Indication type movement analysis & market share 2022 & 2030
  • Fig. 21 Prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 22 Bladder cancer market, 2018 - 2030 (USD Million)
  • Fig. 23 Melanoma market, 2018 - 2030 (USD Million)
  • Fig. 24 Cervical cancer market, 2018 - 2030 (USD Million)
  • Fig. 25 Others market, 2018 - 2030 (USD Million)
  • Fig. 26 Cancer vaccine market: Technology type outlook and key takeaways
  • Fig. 27 Cancer vaccine market: Technology type movement analysis & market share 2022 & 2030
  • Fig. 28 Recombinant cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 29 Whole-cell cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 30 Viral vector and DNA cancer vaccine market, 2018 - 2030 (USD Million)
  • Fig. 31 Other technologies market, 2018 - 2030 (USD Million)
  • Fig. 32 Regional Marketplace: Key Takeaways
  • Fig. 33 Regional Outlook, 2022 & 2030
  • Fig. 34 Regional Market Dashboard
  • Fig. 35 Regional Market Place: Key Takeaways
  • Fig. 36 North America, SWOT Analysis
  • Fig. 37 Europe, SWOT Analysis
  • Fig. 38 Asia Pacific, SWOT Analysis
  • Fig. 39 Latin America, SWOT Analysis
  • Fig. 40 MEA, SWOT Analysis
  • Fig. 41 North America
  • Fig. 42 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Key Country Dynamics
  • Fig. 44 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Canada Key Country Dynamics
  • Fig. 46 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Europe
  • Fig. 48 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 49 UK Key Country Dynamics
  • Fig. 50 UK Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Germany Key Country Dynamics
  • Fig. 52 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 53 France Key Country Dynamics
  • Fig. 54 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Italy Key Country Dynamics
  • Fig. 56 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Spain Key Country Dynamics
  • Fig. 58 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 59 Denmark Key Country Dynamics
  • Fig. 60 Denmark Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 61 Sweden Key Country Dynamics
  • Fig. 62 Sweden Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 63 Norway Key Country Dynamics
  • Fig. 64 Norway Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific
  • Fig. 66 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Japan Key Country Dynamics
  • Fig. 68 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 69 China Key Country Dynamics
  • Fig. 70 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 71 India Key Country Dynamics
  • Fig. 72 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 73 Australia Key Country Dynamics
  • Fig. 74 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 75 Thailand Key Country Dynamics
  • Fig. 76 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 77 South Korea Key Country Dynamics
  • Fig. 78 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Latin America
  • Fig. 80 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil Key Country Dynamics
  • Fig. 82 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Mexico Key Country Dynamics
  • Fig. 84 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 85 Argentina Key Country Dynamics
  • Fig. 86 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 87 MEA
  • Fig. 88 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 89 South Africa Key Country Dynamics
  • Fig. 90 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 91 Saudi Arabia Key Country Dynamics
  • Fig. 92 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 93 UAE Key Country Dynamics
  • Fig. 94 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 95 Kuwait Key Country Dynamics
  • Fig. 96 Kuwait Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 97 Strategy Mapping